See our most recent company presentation to learn more about investing in PharmAla Biotech.
PharmAla Biotech Inc. is a Canadian Biotechnology company dedicated to sourcing of LaNeo™ MDMA in service to the global clinical research community.
Recent regulatory changes in the US have given “Breakthrough” status to treatments based on MDMA. MDMA is currently being investigated for the treatment of a number of disorders.
The Psychedelics market in the US is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD 6,859.95 million by 2027 from USD 2,077.90 million in 2019.
Growing acceptance of psychedelic drugs within clinical settings are factors for the market growth. Psychedelic drugs are used to enhance or change sensory perceptions, energy levels, thought processes, and to facilitate spiritual experiences.
PharmAla’s Intellectual Property provides vertical integration of MDXX compound Chemistry, Manufacturing and Control (CMC)
Novel Chemical Entities
Novel Synthesis Processes
Full scale process development
Formulation and Drug Product IP
|2 Novel MDXX synthesis routes||Q2 2021|
|Provisional patent on 2 Novel MDXX Entities||Q3 2021|
|3 Additional Molecules in Drug Pipeline||Q1 2022|
Swipe the table to see more.
MDMA is under evaluation as a potential treatment for couples therapy, eating disorders, alcohol addiction, anxiety and depression.
PharmAla Biotech is committed to becoming Canada’s first and leading supplier of clinical-grade LaNeo™ MDMA for research purposes.
MDMA – or 3,4- methylenedioxymethamphetamine – is a synthetically-derived psychoactive substance classified as an empathogen. It is not the same as the street drug ecstasy.
Originally synthesized in the early 1900s by Merck, MDMA became more commonly used in the 1970s and early 1980s by some psychiatrists to assist in the treatment of PTSD.
Research into the use of MDMA as a therapeutic agent ceased in the mid-1980s when the USA made the drug illegal, largely due to increased police seizures of streets drugs intended for use in recreational settings.
The first Phase 3 clinical trial for MDMA-assisted PTSD treatment is currently underway in the US, Canada and Israel. The trial is the last step prior to a request for authorization for MDMA-Assisted Psychotherapy in the US. It is expected to be completed as early as 2023.
About 7 or 8 out of every 100 people (or 7-8% of the population) will have PTSD at some point in their lives. About 8 million adults in the US have PTSD during a given year. This is only a small portion of those who have gone through a trauma.
MDMA for clinical trial use is produced to a strict pharmaceutical standard. A regulated dose is administered in a controlled setting by trained health professionals for specific conditions only.
*The efficacy and safety of MDMA-assisted therapy are currently under investigation. MDMA has not yet been approved by Health Canada or any other regulatory body.*